Urofollicle-stimulating hormone must only be used by a physician
experienced in the treatment of infertility.
The urofollicle-stimulating hormone can cause mild to moderate ovarian
enlargement, which may be accompanied by abdominal distension and/or abdominal
pain, which usually relieves within 2 to 3 weeks.
A urofollicle-stimulating hormone can cause severe pulmonary complications
(such as acute respiratory distress syndrome, exacerbation of asthma, etc.) and
ovarian hyperstimulation syndrome, with rare reports of death.
A urofollicle-stimulating hormone can lead to ovarian hyperstimulation
syndrome, which progresses rapidly within 24 hours to several days in severe
cases, manifested as a sharp increase in vascular permeability, resulting in
rapid accumulation of fluid in the thoracic and peritoneal cavities, including
the pericardium. Early symptoms include severe pelvic pain, weight gain, nausea,
and vomiting. Ovarian hyperstimulation syndrome can occur at the end of
treatment, and reach its peak in 7 to 10 days. Follow-up should be followed up
for at least 2 weeks after treatment with urinary follicle-stimulating hormone,
and it will automatically relieve menstrual cramps. Severe cases require drug
withdrawal and hospitalization.
Can cause multiple births, and patients should be informed before the
Follitropin is a prescription drug and must be prescribed by your doctor
for your medical condition.
The above is the relevant content summarized by the editor of Kangyuan
Company. If you want to know more, please continue to pay attention to us. We
will regularly update you about Human chorionic gonadotropin, Human Menopausal
Gonadotropin supplier, Urofollitropin price, Urokinase manufacturer, and Hormone
API Manufacturer Related content, hope to help you.